Welcome to the Tumistic Institute podcast.

Our mission is to promote the Catholic intellectual tradition in the university, the church, and the wider public square.

The lectures on this podcast are organized by university students at Tumistic Institute chapters around the world.

To learn more and to attend these events, visit us at

to mystic institute.org. We're currently seeing explosion of interest by governments,

technology companies, and healthcare systems and genetic testing. They want to use genetic sequencing

to predict individual health risk. Precision medicine, as this model of health care is called, uses AI-based

techniques to combine information from genetics, medical charts, demographics, other data sets like your Fitbit,

to predict the risks facing an individual so that they can be managed.

As former NIH director Francis Collin described it in selling this program, the techniques

of precision medicine will, quote, allow a considerably more useful estimate of your future

risks of illness than is currently possible, enabling a personalized plan of preventive medicine

to be established.

Now, precision medicine is a very popular term for granting agencies and venture capitalists.

So like all such terms, a number of very different research programs have become attached to it.

There's precision oncology, which is kind of treating tumors through sequencing and various kinds of AI-based kind of analysis of the sequence.

Pharmacogenomics, which is simply tying your genotype to the dosing of medication, and the

diagnosis of rare diseases, which is all coming around and I think having significant impacts

in medical treatment in positive ways. But I'm focusing on this idea of diagnosing risk and the role of AI in it.

Now to succeed, precision medicine relies on our genetic information.

For example, direct-to-consumer sequencing companies like the now bankrupt 23 and me

offered consumers' knowledge of their increased

...